TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06787079

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio Tape
Description: Kinesio tape is a non-invasive therapeutic approach that does not involve any medication. It is often used to support tissue and reduce pain.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pilates
Description: Pilates exercises are mind-body exercises that are performed on a mat or with special equipment and focus on strength, core stability, flexibility, muscle control, posture and breathing. Pilates exercises are frequently used to develop elements such as core stability, muscle flexibility and strength, physical fitness and body awareness.

Intervention type: OTHER
Group type: OTHER
Intervention: Pilates
Description: Pilates exercises are mind-body exercises that are performed on a mat or with special equipment and focus on strength, core stability, flexibility, muscle control, posture and breathing. Pilates exercises are frequently used to develop elements such as core stability, muscle flexibility and strength, physical fitness and body awareness.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pilates
Description: Pilates exercises are mind-body exercises that are performed on a mat or with special equipment and focus on strength, core stability, flexibility, muscle control, posture and breathing. Pilates exercises are frequently used to develop elements such as core stability, muscle flexibility and strength, physical fitness and body awareness.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taping will be applied in the same way as kinesio taping, but with plaster tape.
Study: NCT06790602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab Plus Gemcitabine
Description: Cemiplimab Plus Gemcitabine
Study: NCT06791590

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intermittent oro-esophageal
Description: A disposable gastric tube was used to perform enteral nutrition support therapy, and contraindications were evaluated again. Inform the patient and family members of the precautions for intermittent feeding through oral tube, and play the video of the operation process to make them actively cooperate with the operation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Naso-intestinal tube nutrition support
Description: For patients at risk of repeated aspiration and regurgitation, and for patients with gastric nutritional intolerance that cannot be improved by gastrointestinal motivity drugs, indwelling intestinal tube and retropyloric feeding are given.
Study: NCT06792123

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pre-op VR application group
Description: VR application group during preoperative process

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intra-op VR application group
Description: VR application group during intraoperative process
Study: NCT06790823

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The probiotic supplement (Moodamin capsuls)
Description: The probiotic supplement (Moodamin capsuls) provided from Amin pharmacytical company, Iran, was freeze-dried containing Lactobacillus helveticus and Bifidobacterium Longum bacteria at a dose of 2.682 × CFU and 0.318 × CFU each capsule, respectively.Excipients include xylitol, maltodextrin, plum flavor, and malic acid.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The probiotic supplement (Moodamin capsuls) provided from Amin pharmacytical company, Iran, was freeze-dried containing Lactobacillus helveticus and Bifidobacterium Longum bacteria at a dose of 2.682 × CFU and 0.318 × CFU each capsule, respectively. Excipients include xylitol, maltodextrin, plum flavor, and malic acid. A placebo product used for the control group was made up of excipients only.
Study: NCT06792214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirmatrelvir/ritonavir
Description: Paxlovid PO BID for 5 days + standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Veklury IV daily for 5 days + standard of care
Study: NCT05160012

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Comparison Message
Description: In addition to usual care, PCPs will receive a monthly report as an EPIC in basket message describing what category they are in:~1. If HTN control rate \<50th percentile, PCP is told they are below median~2. If HTN control rate is between 50-89th percentile , PCP is told they are below top performer~3. If HTN control rate is between 90-100th percentile, PCP is told they are a high performer
Study: NCT06495320

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rational drug use education
Description: Rational Drug Use Education Program for Parents: The training program consists of 30 minutes. The training program will be delivered to parents in the form of a 30-minute training session with a powerpoint presentation, using the face-to-face education model. Interactive education methods that enable parents' participation will be used. In addition, in order to increase the permanence of education, the educational content will be given to parents in the form of an educational booklet.
Study: NCT05628870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-1358
Description: HRS-1358 or combination with Dalpiciclib Isethionate Tablets will be administered daily orally in continuous dosing over 28-day cycles.
Study: NCT05628402

Intervention type: OTHER
Intervention: Semi-structured interview
Description: The semi-structured interview will take place during a standard follow-up appointment with the therapist already treating the patient after the patient has agreed to participate in the study.
Study: NCT04882358

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ALFAPUMP DSR (DIRECT SODIUM REMOVAL) SYSTEM
Description: Infusion of sodium free Dextrose 10% into peritoneal cavity to remove sodium and fluid using principles of peritoneal dialysis; sodium and ultrafiltrate will be evacuated to the bladder by the alfapump

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ALFAPUMP DSR (DIRECT SODIUM REMOVAL) SYSTEM
Description: Infusion of sodium free Dextrose 10% into peritoneal cavity to remove sodium and fluid using principles of peritoneal dialysis; sodium and ultrafiltrate will be evacuated to the bladder by the alfapump

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor
Description: treatment with a standard dose of SGLT-2 inhibitor
Study: NCT05349214

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAY736
Description: ianalumab s.c.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAY736
Description: ianalumab s.c.
Study: NCT05314543

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoxia
Description: Subjects will be subjected to mild hypoxia simulating an altitude of 1750 m (normobaric hypoxia). Hypoxia decreases oxygen supply to tissue and limit exercise capacity. For this, the subjects will inhale a gas mixture depleted in oxygen (enriched in nitrogen). The barometric pressure at 1500 m being 621 mmHg, PIO2 at this altitude (PIO2 = (621 - 47) x 21%) is 120.5 mmHg. For sea level altitude where the barometric pressure is 760 mmHg, the hypoxic gas mixture should contain (x = 120.5 / (760 - 47)) 16.8% O2. Thus, by inhaling a gas mixture that is oxygen-depleted from 21 to 16.8%, subjects (will simulate the altitude of 1750 and) will experience the equivalent of a 20% reduction in oxygen supply.
Study: NCT05131529

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Taste-focused labels
Description: We will implement taste-focused labels on plant-based dishes in each of the 3 treatment dining halls to re-brand dishes with attributes focused on the taste of the dish (e.g., renaming a Squash with Ginger side to Aromatic Thai Curry Kabocha Squash With Zesty Ginger).
Study: NCT05349214

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo s.c.
Study: NCT05131529

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbon impact labels
Description: We will add labels next to all dishes served in treatment dining halls that indicate whether production of the ingredients in the dish contribute a high, moderate or low amount of carbon emissions. These labels will be absent from the same dishes served in control dining halls. Labels will be added to point-of-service signs, digital menu boards, and menu information on a mobile app.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Changing default menu options
Description: We will make red meat items an opt-in (as opposed to opt-out) item across all meal stations in treatment dining halls. All menu stations will exclude red meat by default, and dining hall patrons will have to request the addition of red meat to meals. At control dining halls, red meat items will be provided by default at meal stations as normal.
Study: NCT05488418

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical, cognitive and biological tests
Description: Evaluations at 1, 3, 6 and 12 months post-inclusion will be performed, during which the subject will complete various clinical and cognitive tests.~A blood sample will be collected at each visit to study biological processes including the regulation of genetic and epigenetic expression, in particular the expression of the GPR56 and ELK1 genes in the blood.~For eligible subjects a brain MRI will be proposed at the first visit.
Study: NCT04816045

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrochemotheraoy
Description: Electrochemotherapy (ECT) is endoscopic electroporation in combination with bleomycin

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electroporation with saline (placebo)
Description: Electroporation in the control group is performed endoscopically with saline
Study: NCT06490614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine in superficial cervical plexus block
Description: While the patient is in the supine position, the head will be turned to the opposite side of the surgical incision, and a line extending from the mastoid process to the clavicular head of the sternomastoid muscle will be marked. Aseptic preparation of this area will be done, and then the block needle will be inserted at the midpoint of this line with injection of bupivacaine 0.25%, 10 mg of Nalbuphine (nalufin 20mg/ml), and adrenaline 1:200,000 in a total volume of 10ml normal saline in the above, below, and middle directions subcutaneously, creating a sausage-shaped swelling. The sensory block will be assessed with ice chips in the dermatome corresponding to the block, which included the skin of the neck, upper chest, shoulder, and ear, until the completion of the sensory blockade.
Study: NCT05606380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX60
Description: HLX60(anti-GARP Monoclonal Antibody）have 5 dose cohorts: 0.5, 2, 5, 15, 25mg/kg, intravenous infusion, every 3 weeks.
Study: NCT06494345

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Genolair, solution for subcutaneous administration, 150 mg
Description: Genolair (omalizumab), solution for subcutaneous administration, 150 mg for single subcutaneous administration

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Genolair, lyophilisate for the preparation of solution for subcutaneous administration
Description: Genolair (omalizumab), lyophilisate for the preparation of solution for subcutaneous administration, 150 mg for single subcutaneous administration

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Xolair®, solution for subcutaneous administration, 150 mg
Description: Xolair® (omalizumab), solution for subcutaneous administration, 150 mg for single subcutaneous administration
Study: NCT05778864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3473329
Description: Administered orally.
Study: NCT04714944

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Supplementation period 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whole fiber product
Description: Supplementation period 12 weeks
Study: NCT05074667

Intervention type: DEVICE
Group type: OTHER
Intervention: Continuous Glucose Monitor
Description: Participants will be provided a continuous glucose monitor for use in self-glucose monitoring as per standard clinical care

Intervention type: OTHER
Group type: OTHER
Intervention: Patient Reported Outcome Questionnaires
Description: Participants and their parents will be asked to complete patient reported outcome questionnaires at 3 study time points.
Study: NCT04619095

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Psyllium
Description: See the information already included in the arm descriptions.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: See the information already included in the arm descriptions.
Study: NCT04715932

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hesperidin
Description: Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.
Study: NCT05778864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3473329
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3473329
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3473329
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3473329
Description: Administered orally.
Study: NCT03621904

Intervention type: DRUG
Intervention: Hormonal Antineoplastics
Description: Hormonal therapy used for treatment in endometrial cancer patients
Study: NCT05365958

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV Podcast for Heterosexual African American Adults
Description: The video podcast will deliver HIV prevention messages using entertainment education and behavioral journalism, and film production techniques such as talking head video, interview, animations, \& live-action skits. The research team will work closely with the production company in scripting the video vignettes and sequences, ensuring that video content reflects salient domains captured in the concept mapping research development phase of the study.
Study: NCT05738798

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oral immunotherapy
Description: oral immunotherapy is performed by freely available, widely used food products, regularly part of a normal infant's diet such as peanut butter or boiled egg.
Study: NCT06113744

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: saline

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: saline

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 Vaccine (Vero Cell) ,Inactivated
Description: COVILO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 mRNA Vaccine (ZSVG-02-O) 10 μg
Description: Low-dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 mRNA Vaccine (ZSVG-02-O) 10 μg
Description: Low-dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 mRNA Vaccine (ZSVG-02-O) 30 μg
Description: Mid-dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 mRNA Vaccine (ZSVG-02-O) 30 μg
Description: Mid-dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 mRNA Vaccine (ZSVG-02-O) 60 μg
Description: High-dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 mRNA Vaccine (ZSVG-02-O) 60 μg
Description: High-dose
Study: NCT06436365

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Locking expert intramedullary nail fixation
Description: the fracture was reduced to enable the insertion of the guide wire to restore the rotation, length, and angulation. Poller screws were used as control deformity by narrowing the medullary canal and were inserted on the deformity concave side between the nail and bone cortex. A ball-ended guidewire was placed through the entry point to the tibial canal and then to the tibial fracture site under the guidance of fluoroscopy. The guide wire should be inserted centrally within the distal segment on both lateral and anteroposterior views and be far about 1 to 0.5 centimeters from the ankle joint. Reamers with deep fluted and small diameters were used slowly to increase the diameter to reach 0.5 mm till the cortical chatter.~The nail was inserted by attachment of insertion device and locking of the proximal screw to the nail by directing its apex posteriorly. The nail insertion was done by flexing the knee to prevent any patellar impingement.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distal locked plate
Description: Cobb dissector was used in creation extra-periosteal subcutaneous tunnel for gentle introduction of a proper plate which was determined by choosing appropriate size and level guided by imaging which helped in prevention of any periosteal damage. Manual closed reduction was performed using the percutaneous clamps. Distal screws were positioned as the following, one was inserted above the medial malleolus, another one was inserted right and below the fracture, and the other screws were inserted to help in anatomical plate positioning. By reduction preservation, proximal screws were inserted by small incisions which was followed by insertion of the remained distal screws.
Study: NCT04946747

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Modern microelectrical mechanical systems (MEMS) head-impact sensors
Description: Both groups will wear our smart head-impact sensor system (MEMS head-impact sensors) to measure their response to training.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Modern microelectrical mechanical systems (MEMS) head-impact sensors
Description: Both groups will wear our smart head-impact sensor system (MEMS head-impact sensors) to measure their response to training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality (VR) Goggle Use with consistent timing of Conditioned Stimulus and Unconditioned Stimulus
Description: The Trained group will have the conditioned stimulus (CS, images of opposing players approaching) and the unconditioned stimulus (US, a voice cue to stiffen the neck by the coach) always being delivered with a consistent timing relationship (e.g. a 250 msec delay between the CS and the US), causing the conditioned response (neck stiffening) to emerge.
Study: NCT06055049

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention (Kinesio Taping) group
Description: It is the group to which Kinesio Taping applied.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intervention (Kinesio Taping) group
Description: It is the group to which Kinesio Taping applied.
Study: NCT06410469

Intervention type: PROCEDURE
Intervention: rug weaving-like plication technique
Description: anterior vaginal wall repair with the rug weaving-like plication technique in cystosel
Study: NCT05437913

Intervention type: OTHER
Group type: OTHER
Intervention: Psychological intervention (self-compassion based)
Description: 4 weeks intervention for both primary caregivers and adolescents with T1D will be done online through videoconferencing and will be based on three validated protocols that use self-compassion (MSC and MSC Teens).
Study: NCT06303479

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-Instrumental breathing exercise group
Description: Before starting the exercises, participants will be told about diaphragmatic breathing exercises, maximum inspiratory holding technique and thoracic expansion exercises through the Zoom program by telerehabilitation method, and people will be checked by the physiotherapist who manages the program during the practice. The program will last for 8 weeks and will be planned to be implemented 5 days a week in total, including 2 days of telerehabilitation, 3 days of home program. The participant will be asked to start the exercises in a reclining position with his back to the chair. He will be asked to place his right hand on his upper abdomen and his left hand on the upper side of his chest. In each session, the exercises will be performed with 1 set of 10 repetitions for each of the diaphragmatic breathing and thoracic expansion exercises and will progress with progression.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instrumental breathing exercise group
Description: The volume-oriented spirometer works with pressure and its indicator changes during breathing. When the participants breathe, the pressure in the tube decreases and the piston of the spirometer rises. The inhaled breath volume is seen at the top of the piston. In our study, participants will be told about the exercises through the Zoom program using the telerehabilitation method, and people will be checked by the responsible physiotherapist who manages the program during the application. The program will last for 8 weeks, 2 days of telerehabilitation, 3 days of home program will be planned to be implemented 5 days a week in total. Participants will be instructed to breathe up to their total lung capacity and maintain continuous inspiration for at least 3 seconds. The exercises will start with 1 set of 15 repetitions and the program will progress with progression.
Study: NCT05533827

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kaleidoscope
Description: Kaleidoscope

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kaleidoscope
Description: Kaleidoscope
Study: NCT04946747

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality (VR) Goggle Use with inconsistent timing of Conditioned Stimulus and Unconditioned Stimulus
Description: The Control group will also receive the same CS and the same US as trained group, but the CS and the US will bear no consistent timing relationship, therefore never causing any CR to emerge.
Study: NCT05533827

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kaleidoscope
Description: Kaleidoscope

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Music
Study: NCT05952973

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SkillTalk
Description: Online Educator Mircoskill Training and Parent Microskill Training
Study: NCT05114707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: camrelizumab
Description: Camrelizumab was administrated with 200mg each time, every three weeks for a total of 11 cycles since the first day of induction chemotherapy.